Securities code: Fujian Cosunter Pharmaceutical Co.Ltd(300436) securities abbreviation: Fujian Cosunter Pharmaceutical Co.Ltd(300436) Announcement No.: 2022024 Fujian Cosunter Pharmaceutical Co.Ltd(300436)
Announcement on the resolution of the 11th meeting of the 4th board of supervisors
The company and all members of the board of supervisors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Meetings of the board of supervisors
Fujian Cosunter Pharmaceutical Co.Ltd(300436) (hereinafter referred to as “the company”) the 11th meeting of the 4th board of supervisors was notified by e-mail on March 4, 2022 and held in the conference room on the third floor of the company, block B, building 10, software park, No. 89, software Avenue, Gulou District, Fuzhou, Fujian Province on March 9, 2022. The meeting was presided over by the chairman of the board of supervisors. Three supervisors should be present at the meeting, three actually present, and all three supervisors participated in the voting. The meeting was held in accordance with the provisions of the company law and the articles of association.
2、 Deliberation at the meeting of the board of supervisors
1. The proposal on signing technical service contracts and related party transactions was deliberated and adopted
After review, the board of supervisors believes that this connected transaction is the normal business of the company and its partners. Both parties to the transaction follow the principle of fair market pricing, and there is no situation that damages the legitimate rights and interests of the company and shareholders, especially small and medium-sized shareholders; When the board of directors considered the related party transaction, the related directors had avoided voting, and the relevant decision-making procedures were legal and compliant, in line with the Shenzhen Stock Exchange gem stock listing rules, the company’s related party transaction rules and other relevant provisions. The board of supervisors agreed to this connected transaction and agreed to submit it to the general meeting of shareholders for deliberation.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on signing technical service contract and related party transactions (Announcement No.: 2022025).
The proposal was considered and adopted by 2 votes in favor, 0 against and 0 abstention. Mr. Guo Xiaoyang, a related supervisor, avoided voting. This proposal must be submitted to the general meeting of shareholders for deliberation.
2. The proposal on using raised funds to increase capital to subsidiaries to implement projects invested with raised funds was deliberated and adopted
After review, the board of supervisors believes that the capital increase of the company to Fujian Fujian Cosunter Pharmaceutical Co.Ltd(300436) Jintang Pharmaceutical Co., Ltd. (hereinafter referred to as “Jintang pharmaceutical”) is conducive to the smooth implementation of the raised investment project, the improvement of the use efficiency of the raised funds and the full play of the benefits, as well as the improvement of the company’s innovation and transformation ability and comprehensive competitiveness, It is in line with the use plan of raised funds and the company’s development strategy and long-term plan, and in line with the interests of the company and all shareholders. There is no situation that damages the legitimate rights and interests of the company and shareholders, especially small and medium-sized shareholders. The company’s capital increase to the implementation subject of the raised investment project has fulfilled the relevant procedures of the company’s decision-making, and complies with the guidelines for the supervision of listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies Laws, regulations, normative documents, articles of association and other relevant provisions, such as Shenzhen Stock Exchange self regulatory guidelines for listed companies No. 2 – standardized operation of GEM listed companies, and relevant deliberation and voting procedures are legal and effective. It is agreed that the company will increase the capital of Jintang pharmaceutical, the implementation subject of the raised investment project.
For details, the company disclosed on cninfo.com on the same day（ http://www.cn.info.com.cn. ）Announcement on using raised funds to increase capital to subsidiaries to implement raised investment projects (Announcement No.: 2026).
The proposal was considered and adopted by 3 votes in favor, 0 against and 0 abstention.
3、 Documents for future reference
1. Resolutions of the 11th meeting of the 4th board of supervisors;
2. Other documents required by Shenzhen Stock Exchange.
It is hereby announced.
Fujian Cosunter Pharmaceutical Co.Ltd(300436) board of supervisors
March 9, 2022
